JP2021522211A5 - - Google Patents
Info
- Publication number
- JP2021522211A5 JP2021522211A5 JP2020558435A JP2020558435A JP2021522211A5 JP 2021522211 A5 JP2021522211 A5 JP 2021522211A5 JP 2020558435 A JP2020558435 A JP 2020558435A JP 2020558435 A JP2020558435 A JP 2020558435A JP 2021522211 A5 JP2021522211 A5 JP 2021522211A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- alkyl
- carbon atoms
- alkoxy
- halo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023167782A JP2023165946A (ja) | 2018-04-16 | 2023-09-28 | Ｅｐ４阻害剤およびその使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862658494P | 2018-04-16 | 2018-04-16 | |
| US62/658,494 | 2018-04-16 | ||
| US201862737219P | 2018-09-27 | 2018-09-27 | |
| US62/737,219 | 2018-09-27 | ||
| PCT/US2019/027603 WO2019204257A1 (en) | 2018-04-16 | 2019-04-16 | Ep4 inhibitors and use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023167782A Division JP2023165946A (ja) | 2018-04-16 | 2023-09-28 | Ｅｐ４阻害剤およびその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021522211A JP2021522211A (ja) | 2021-08-30 |
| JP2021522211A5 true JP2021522211A5 (enExample) | 2022-04-25 |
Family
ID=66589884
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020558435A Pending JP2021522211A (ja) | 2018-04-16 | 2019-04-16 | Ｅｐ４阻害剤およびその使用 |
| JP2023167782A Pending JP2023165946A (ja) | 2018-04-16 | 2023-09-28 | Ｅｐ４阻害剤およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023167782A Pending JP2023165946A (ja) | 2018-04-16 | 2023-09-28 | Ｅｐ４阻害剤およびその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US10973834B2 (enExample) |
| EP (1) | EP3781162A1 (enExample) |
| JP (2) | JP2021522211A (enExample) |
| CN (1) | CN112292128A (enExample) |
| AU (1) | AU2019255196A1 (enExample) |
| CA (1) | CA3096546A1 (enExample) |
| WO (1) | WO2019204257A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112292128A (zh) | 2018-04-16 | 2021-01-29 | 阿瑞斯医疗有限公司 | Ep4抑制剂和其用途 |
| US20210315909A1 (en) | 2018-07-11 | 2021-10-14 | Arrys Therapeutics, Inc. | Polymorphic compounds and uses thereof |
| LT3860998T (lt) | 2018-10-05 | 2024-06-25 | Annapurna Bio Inc. | Junginiai ir kompozicijos, skirti gydyti būkles, susijusias su apj receptoriaus aktyvumu |
| EP3722319A1 (en) * | 2019-04-09 | 2020-10-14 | Rottapharm Biotech S.r.l. | Pharmaceutical combination of an ep4 antagonist and immune checkpoint inhibitors for the treatment of tumours |
| CN110386941A (zh) * | 2019-08-15 | 2019-10-29 | 上海邦耀生物科技有限公司 | Ep4受体拮抗剂和pd-1抑制剂联合用于癌症的治疗 |
| WO2021205367A1 (en) * | 2020-04-08 | 2021-10-14 | Askat Inc. | Use of ep4 receptor antagonists for the treatment of liver cancer, melanoma, lymphoma and leukemia |
| WO2021226162A1 (en) * | 2020-05-05 | 2021-11-11 | Arrys Therapeutics, Inc. | Ep4 antagonists and their use in the treatment of proliferative diseases |
| WO2022020114A2 (en) | 2020-07-10 | 2022-01-27 | Ting Therapeutics Llc | Methods for the prevention and treatment of hearing loss |
| EP4215214A4 (en) * | 2020-09-16 | 2024-07-03 | Osaka University | THERAPEUTIC AGENT AGAINST CANCER, IMMUNOSTIMULANT AND SCREENING METHOD FOR ANTI-CANCER SUBSTANCE |
| CN114907267A (zh) * | 2021-02-08 | 2022-08-16 | 中国科学院上海药物研究所 | 用于抗肿瘤的药物组合 |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HN2001000224A (es) | 2000-10-19 | 2002-06-13 | Pfizer | Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos. |
| CA2536870C (en) | 2003-09-03 | 2009-10-27 | Pfizer Inc. | Phenyl or pyridyl amide compounds as prostaglandin e2 antagonists |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| AU2006221699A1 (en) | 2005-03-11 | 2006-09-14 | Pfizer Inc. | Crystal forms of an imidazole derivative |
| JP5238936B2 (ja) | 2005-03-25 | 2013-07-17 | ジーアイティーアール，インク． | Ｇｉｔｒ結合分子およびその使用 |
| DK1879573T3 (da) | 2005-05-10 | 2013-02-25 | Incyte Corp | Modulatorer af indolamin 2,3-dioxygenase og fremgangsmåder til anvendelse deraf |
| KR101704734B1 (ko) | 2005-07-01 | 2017-02-09 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| ES2540561T3 (es) | 2005-12-20 | 2015-07-10 | Incyte Corporation | N-hidroxiamidinoheterociclos como moduladores de indolamina 2,3-dioxigenasa |
| CA2663057C (en) | 2006-09-19 | 2015-12-08 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| CL2007002650A1 (es) | 2006-09-19 | 2008-02-08 | Incyte Corp | Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras. |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| PT2175884T (pt) | 2007-07-12 | 2016-09-21 | Gitr Inc | Terapias de combinação empregando moléculas de ligação a gitr |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| WO2009073620A2 (en) | 2007-11-30 | 2009-06-11 | Newlink Genetics | Ido inhibitors |
| EP2296789A1 (fr) | 2008-05-29 | 2011-03-23 | Saint-Gobain Centre de Recherches et d'Etudes Européen | Structure en nid d'abeille a base de titanate d'aluminium |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| MX356367B (es) | 2008-12-09 | 2018-05-25 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t. |
| CA2754702C (en) * | 2009-04-22 | 2016-06-07 | Yukinori Take | Selective ep4 antagonistic substance for treatment of cancer |
| JP5594754B2 (ja) | 2009-07-13 | 2014-09-24 | 国立大学法人 東京大学 | 運行実績を活用したオンデマンドバスの運行スケジューリングシステム及びその方法 |
| IN2015DN02826A (enExample) | 2009-09-03 | 2015-09-11 | Merck Sharp & Dohme | |
| EP2493862B1 (en) | 2009-10-28 | 2016-10-05 | Newlink Genetics Corporation | Imidazole derivatives as ido inhibitors |
| DK2510010T3 (en) | 2009-12-10 | 2015-12-14 | Hoffmann La Roche | Antibodies that bind to human CSF1R extracellular domain 4 and their use |
| CA2789665C (en) | 2010-02-22 | 2020-06-16 | Askat Inc. | Use of ep4 receptor antagonists in the treatment of il-23 mediated diseases |
| DK2542256T3 (da) | 2010-03-04 | 2019-08-26 | Macrogenics Inc | Antistoffer reagerende med b7-h3, immunologisk aktive fragmenter deraf og anvendelser deraf |
| CN102918061B (zh) | 2010-03-05 | 2016-06-08 | 霍夫曼-拉罗奇有限公司 | 针对人csf-1r的抗体及其用途 |
| EP3943154A1 (en) | 2010-05-04 | 2022-01-26 | Five Prime Therapeutics, Inc. | Antibodies that bind csf1r |
| NZ729044A (en) | 2010-09-09 | 2020-07-31 | Pfizer | 4-1bb binding molecules |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| NO2694640T3 (enExample) | 2011-04-15 | 2018-03-17 | ||
| CA2833636A1 (en) | 2011-04-20 | 2012-10-26 | Amplimmune, Inc. | Antibodies and other molecules that bind b7-h1 and pd-1 |
| BR112014012819B1 (pt) | 2011-11-28 | 2022-08-16 | Merck Patent Gmbh | Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição |
| WO2013090552A1 (en) | 2011-12-13 | 2013-06-20 | Yale University | Compositions and methods for reducing ctl exhaustion |
| MX356337B (es) | 2011-12-15 | 2018-05-23 | Hoffmann La Roche | Anticuerpos contra csf-1r humano y sus usos. |
| MX2014008961A (es) | 2012-02-06 | 2014-10-14 | Genentech Inc | Composiciones y metodos para utilizar inhibidores de csf1r. |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| KR20150018533A (ko) | 2012-05-11 | 2015-02-23 | 파이브 프라임 테라퓨틱스, 인크. | 콜로니 자극 인자 1 수용체(csf1r)에 결속하는 항체들에 의한 질병 상태의 치료 방법 |
| AR091649A1 (es) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
| CN107759690A (zh) | 2012-08-31 | 2018-03-06 | 戊瑞治疗有限公司 | 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法 |
| US10391086B2 (en) | 2013-03-19 | 2019-08-27 | Askat Inc. | Use of EP4 receptor antagonists in the treatment of cartilage disease |
| KR20150130404A (ko) | 2013-03-19 | 2015-11-23 | 에스크엣 인크. | 연골질환 치료에서의 ep4 수용체 길항제의 용도 |
| CA2997692A1 (en) | 2014-03-06 | 2015-09-11 | Aratana Therapeutics, Inc. | Crystalline forms of grapiprant |
| SG11201609770TA (en) * | 2014-05-23 | 2016-12-29 | Eisai R&D Man Co Ltd | Combination therapies for the treatment of cancer |
| UY36390A (es) * | 2014-11-05 | 2016-06-01 | Flexus Biosciences Inc | Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen |
| MX385428B (es) * | 2016-07-07 | 2025-03-04 | Ono Pharmaceutical Co | Combinación que comprende antagonista del receptor 4 de prostaglandina e2 (ep4) e inhibidor de punto de control inmunitario. |
| US20190365680A1 (en) | 2016-11-04 | 2019-12-05 | Askat Inc. | Use of ep4 receptor antagonists for the treatment of nash-associated liver cancer |
| US10342785B2 (en) | 2016-11-04 | 2019-07-09 | Askat Inc. | Use of EP4 receptor antagonists for the treatment of NASH-associated liver cancer |
| CN112292128A (zh) * | 2018-04-16 | 2021-01-29 | 阿瑞斯医疗有限公司 | Ep4抑制剂和其用途 |
| US20210315909A1 (en) | 2018-07-11 | 2021-10-14 | Arrys Therapeutics, Inc. | Polymorphic compounds and uses thereof |
| IL280051B2 (en) | 2018-07-11 | 2024-03-01 | Arrys Therapeutics Inc | EP4 inhibitors and their synthesis |
| CA3113468A1 (en) | 2018-09-27 | 2020-04-02 | Arrys Therapeutics, Inc. | Grapiprant unit dosage forms |
| WO2021205367A1 (en) * | 2020-04-08 | 2021-10-14 | Askat Inc. | Use of ep4 receptor antagonists for the treatment of liver cancer, melanoma, lymphoma and leukemia |
-
2019
- 2019-04-16 CN CN201980033839.6A patent/CN112292128A/zh active Pending
- 2019-04-16 AU AU2019255196A patent/AU2019255196A1/en not_active Abandoned
- 2019-04-16 US US16/385,524 patent/US10973834B2/en active Active
- 2019-04-16 WO PCT/US2019/027603 patent/WO2019204257A1/en not_active Ceased
- 2019-04-16 JP JP2020558435A patent/JP2021522211A/ja active Pending
- 2019-04-16 CA CA3096546A patent/CA3096546A1/en active Pending
- 2019-04-16 EP EP19724972.5A patent/EP3781162A1/en not_active Withdrawn
-
2021
- 2021-03-01 US US17/187,900 patent/US20210290641A1/en not_active Abandoned
-
2023
- 2023-07-19 US US18/355,232 patent/US20240066040A1/en not_active Abandoned
- 2023-09-28 JP JP2023167782A patent/JP2023165946A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kwapisz | Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib | |
| Jhaveri et al. | A phase II open-label study of ganetespib, a novel heat shock protein 90 inhibitor for patients with metastatic breast cancer | |
| RU2597844C2 (ru) | Введение гипоксически активируемых пролекарств и средств, препятствующих ангиогенезу, для лечения рака | |
| Konings et al. | The applicability of mTOR inhibition in solid tumors | |
| JP6640288B2 (ja) | 卵巣癌の治療のための併用療法 | |
| Hashimoto et al. | Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer | |
| O’Sullivan | Overcoming endocrine resistance in hormone-receptor positive advanced breast cancer-the emerging role of CDK4/6 inhibitors | |
| Polk et al. | Specific CDK4/6 inhibition in breast cancer: a systematic review of current clinical evidence | |
| Leung et al. | Potentiation of growth inhibitory responses of the mTOR inhibitor everolimus by dual mTORC1/2 inhibitors in cultured breast cancer cell lines | |
| JP2015532292A5 (enExample) | ||
| RU2018111439A (ru) | Новое пиразоло[3, 4-d]пиримидиновое соединение или его соль | |
| MX2014011925A (es) | Dosificacion y administracion de anticuerpos monoespecíficos y biespecíficos anti- igf 1r y anti erbb3. | |
| MX2011000440A (es) | Combinacion de (a) un inhibidor de fosfoinositido 3-cinasa y (b) un modulador de la ruta de ras/raf/mek. | |
| JP2013531069A (ja) | ４−ヨード−３−ニトロベンズアミド及びイリノテカンを用いる転移性乳癌の治療方法 | |
| KR20150038593A (ko) | 교모세포종의 치료를 위한 조합 요법 | |
| WO2013138371A1 (en) | Methods for treating pancreatic cancer using combination therapies comprising an anti-erbb3 antibody | |
| JP2014533277A5 (enExample) | ||
| TN2012000493A1 (en) | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations | |
| US20160303232A1 (en) | Combination treatments with seribantumab | |
| JP2013511487A (ja) | Ｃｄｃ７阻害剤と抗新生物薬とを含む治療用の組み合わせ | |
| D Husseinzadeh et al. | Therapeutic rationale for mTOR inhibition in advanced renal cell carcinoma | |
| Martino et al. | Selinexor in multiple myeloma | |
| US20230235077A1 (en) | Materials and methods of treating cancer | |
| Juengel et al. | Combining the receptor tyrosine kinase inhibitor AEE788 and the mammalian target of rapamycin (mTOR) inhibitor RAD001 strongly inhibits adhesion and growth of renal cell carcinoma cells | |
| Wang et al. | AKT is critically involved in the antagonism of BRAF inhibitor sorafenib against dabrafenib in colorectal cancer cells harboring both wild-type and mutant (V600E) BRAF genes |